Cancer Vaccines

Name
Cancer Vaccines
Accession Number
DBCAT001835
Description

Not Available

Drugs
DrugDrug Description
Sipuleucel-TAn autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
VEGFR2-169VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).
Nelipepimut-SInvestigated for use/treatment in prostate cancer and breast cancer.
Drugs & Drug Targets
DrugTargetType
Sipuleucel-TProstatic acid phosphatasetarget
Nelipepimut-SHLA class I histocompatibility antigen, A-2 alpha chaintarget
Nelipepimut-SHLA class I histocompatibility antigen, A-3 alpha chaintarget